Form 8-K Mirum Pharmaceuticals, For: Dec 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- NVIDIA (NVDA) Tops Q2 EPS by 14c, Offers Guidance
Mirum sues generic drugmakers over Livmarli patent infringement
December 19, 2025 4:08 PM ESTMirum Pharmaceuticals Inc. (NASDAQ: MIRM) filed patent infringement lawsuits on December 19, 2025, against four generic drug manufacturers in the United States District Court for the District of Delaware.
The company sued Sandoz Inc., Annora Pharma Private Limited, Zydus Lifesciences Global FZE, and Zenara Pharma Private... More
